- Events & ActivityEvents & Activity
- Notification of Full Year Results
- Update on Lupuzor Phase III Study
- New Employee Share Option Plan & Grant of Options
- ImmuPharma to present at Master Investor Show
- Holding(s) in Company
- Â£4.1 Million Fund Raise via Accelerated Bookbuild
- Accelerated Bookbuild for the Issue of Equity
- Change of Adviser
- Update on Lupuzor Pivotal Phase III Study
- Update on Cancer Compound IPP-204106 'Nucant'
ImmuPharma PLC (IMM:LSE) closed at 54.50, -22.50% below its 52-week high of 70.32, set on Feb 17, 2017.
27.12May 23 201670.32Feb 17 2017
Markit short selling activity
|Market cap||70.67m GBP|
|EPS (TTM)||-0.0601 GBP|
Data delayed at least 20 minutes, as of May 23 2017 16:51 BST.